StreetAlpha.app
Home › Stocks › ACTU

Actuate Therapeutics, Inc. (ACTU)

$0.23
▲ +5.38%
LAST CLOSE · NOV 20

Actuate Therapeutics develops elraglusib, an experimental cancer drug that targets the GSK-3β enzyme in tumors. It last closed at $0.23 on Nov 20, up 5.38% on the day. For the quarter ended Sep 2026, ACTU reported EPS of -$0.14. Over the last 12 months ACTU insiders bought $50K of stock on the open market and sold $1.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is ACTU in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACTU.

Key Stats

Last 12 months
Results
Net income
−$18.5M
EPS (diluted)
−$0.76
−323.5% vs a year ago
Valuation
Market cap
$13.6M
60.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.1M
At Sep 30
Debt
$405K
At Sep 30
Shareholder equity
−$809K
Shares outstanding
60.4M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$24.7M−$24.7MFY2023FY2024: −$27.3M−$27.3MFY2024FY2025: −$22.2M−$22.2MFY2025

From ACTU's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.14
Quarter ended Sep 2026
Year ago EPS
-$0.25
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.22Dec '24Mar 2025: -$0.32Mar '25Jun 2025: -$0.30Jun '25Sep 2025: -$0.25Sep '25Dec 2025: -$0.18Dec '25Mar 2026: -$0.24Mar '26Jun 2026: -$0.20Jun '26Sep 2026: -$0.14Sep '26Latest -$0.14
Revenue by quarter
Not enough quarters on file yet.
StreetAlpha's call on ACTUStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ACTU
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACTU

Technical Analysis

ACTU · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 150% below its 50 day average. It is 696% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $0.22, and the nearest resistance the Pivot R1 at $0.25.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 34.0%/day
Key levels
$7.9052 week high+3334.8%
$1.79200 day average+678.3%
$0.93100 day average+304.3%
$0.5650 day average+143.5%
$0.35Swing high (Nov 12)+52.2%
$0.3220 day average+39.1%
$0.25Pivot R1+8.7%
$0.23Last close
$0.22Pivot−4.3%
$0.20Pivot S1−13.0%
$0.1752 week low−26.1%
Indicators
RSI (14)27.97Oversold below 30Oversold
MACD-0.10Above its signal lineBullish
Stochastic18.3Near the bottom of its rangeOversold
ADX (14)28.9Trending down
Williams %R-75.1Oversold below −80, overbought above −20Neutral
CCI (20)-140.0Oversold below −100, overbought above 100Oversold
Rate of change−31.5%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 34.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACTU

What happened before

See how ACTU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for ACTUHow many large options trades hit ACTU, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ACTU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼9 buying vs 42 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -24
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4064−37.5%
In funds' top 10110.0%
Held by funds22.0%22.4%−0.4 pts
New / increased4 / 516 / 18−73.5%
Reduced / sold out15 / 2720 / 14+23.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACTU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACTU Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$50K1 buy · 1 insider
Sold$1.6M1 sale · 1 insider
2026-01 sold $1.6M2026-10 bought $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 28Daniel M SchmittPresident, CEO and DirectorBuy140,844$0.35$50K
Jan 5Todd S ThomsonDirectorSale280,000$5.80$1.6M
Jun 27, 2025BIOS Actuate Co-Invest I, LPDirectorBuy71,428$7.00$500K
Jun 27, 2025BIOS Fund II, LPDirectorBuy71,428$7.00$500K
Jun 27, 2025Bios Equity COF, LPDirectorBuy71,428$7.00$500K
Every insider buy and sale for ACTU over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACTU insider trades →

From SEC Form 4 filings by ACTU's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACTU is in one of them and how their past ACTU trades turned out.

ACTU in the AI portfolios
Loading…

ACTU News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACTU in an article yet. Here's the latest on the wider market.

ACTU in the news

About Actuate Therapeutics

Actuate Therapeutics is a biopharmaceutical company based in Fort Worth, Texas. It is developing elraglusib, an experimental cancer drug designed to block an enzyme that helps tumors survive and grow. The company is testing the drug mainly in pancreatic cancer, and it is also studying pediatric cancers and other tumor types. It is developing both an injectable form and an oral tablet for patients with difficult to treat cancers.

Headquarters
Fort Worth, TX